Comparative Pharmacology
Head-to-head clinical analysis: ADENOSINE versus PRONESTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSINE versus PRONESTYL.
ADENOSINE vs PRONESTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts as a non-selective agonist at adenosine A1, A2A, A2B, and A3 receptors. It slows atrioventricular (AV) conduction through activation of A1 receptors, which increases potassium efflux and reduces calcium influx, hyperpolarizing nodal cells and prolonging refractoriness. This terminates reentrant supraventricular tachyarrhythmias involving the AV node.
Class IA antiarrhythmic; blocks sodium channels, decreases phase 0 upstroke velocity, prolongs action potential duration, and increases effective refractory period.
Paroxysmal supraventricular tachycardia: 6 mg rapid IV bolus over 1-2 seconds; if no conversion in 1-2 minutes, give 12 mg rapid IV bolus; may repeat 12 mg once if necessary. Maximum single dose: 12 mg. Also used for cardiac stress testing: 140 mcg/kg/min IV infusion over 6 minutes, total dose 0.84 mg/kg.
For life-threatening ventricular arrhythmias: loading dose of 100 mg IV over 5 minutes, repeated every 5 minutes as needed up to a total of 1 g. Maintenance: continuous IV infusion of 1-4 mg/min. Oral: 50 mg/kg/day in divided doses every 3-6 hours.
None Documented
Clinical Note
moderateCarbamazepine + Adenosine
"The risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine."
Clinical Note
moderateTheophylline + Adenosine
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline."
Clinical Note
moderateDyphylline + Adenosine
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Dyphylline."
Clinical Note
moderateAminophylline + Adenosine
None Documented
Terminal elimination half-life <10 seconds (rapidly cleared from plasma by cellular uptake and metabolism); clinical context: transient effects require continuous IV infusion for sustained action.
3-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment. Clinical context: Requires dosing every 3-4 hours to maintain therapeutic levels; sustained-release formulations allow Q6-8h dosing.
Hepatic metabolism (primarily via adenosine deaminase and adenosine kinase) to inosine and AMP; renal excretion of metabolites accounts for <10% of elimination.
Renal excretion accounts for approximately 50-60% of procainamide elimination as unchanged drug, with an additional 10-30% as the active metabolite N-acetylprocainamide (NAPA). Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic
"The therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline."